Increasing incidence of lung cancer, in turn, rising demand for early diagnosis is a key factor driving lung cancer screening market revenue growth

Read More: https://www.emergenresearch.com/industry-report/lung-cancer-screening-market

The global lung cancer screening market size was USD 2.80 Billion in 2021 and is expected to register a revenue CAGR of 8.1% during the forecast period, according to latest analysis by Emergen Research. High cigarette consumption increasing incidence of lung cancer is a major factor driving market revenue growth.

Lung cancer is one of the main causes of cancer death, accounting for around 25% of all cancer fatalities. Cigarette smoking has been identified as a significant risk factor for developing Non-Small Cell Lung Cancer (NSCLC), along with other environmental and genetic risk factors. Approximately 80% of lung cancer fatalities are caused by smoking, with remaining being caused by secondhand smoke exposure. According to World Health Organization, rise in worldwide tobacco consumption, particularly in Asia, is responsible for a continued rise in lung cancer mortality. In addition, lung cancer cases has been increased due to factors such as water pollution, age, radiation exposure, air pollution (polycyclic aromatic hydrocarbons), and prolonged exposure to certain chemicals, gases, or pollutants including asbestos, beryllium, arsenic, nickel, and chromium. With the advent of genetic and biomarker testing, which has several potential prospects in the market, certain mutations have been found for better-personalized target treatment for patients, thus, there is a rise in demand for lung cancer screening for early diagnosis, which is driving revenue growth of the market.